Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunogenicity of Oral Norovirus Vaccine in Older Adults
NCT04854746Phase 1Completed
- Sponsor
- Vaxart, Inc.
- Start
- Apr 2021
- Primary completion
- Jan 2022
- Modality
- Drug Delivery Systems, Vaccines & Immunotherapeutics, Adenoviral Vectors
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of VXA-GI.1.NN in norovirus infection (6 arms), sponsored by Vaxart, Inc. Primary endpoints: Rate of Solicited Adverse Events and Rate of Unsolicited Adverse Events. Started Apr 2021; status: completed.
02
Drugs
VXA-GI.1.NN
03
Conditions
norovirus infection
Beyond the preview
Go deeper on NCT04854746.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04854746.